Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United Stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghatalia, Pooja, Zibelman, Matthew, Geynisman, Daniel M., Plimack, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066800/
https://www.ncbi.nlm.nih.gov/pubmed/30083254
http://dx.doi.org/10.1177/1758835918788310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066800/
https://www.ncbi.nlm.nih.gov/pubmed/30083254
http://dx.doi.org/10.1177/1758835918788310

Ejemplares similares